Science you can understand. Quality you can verify.
Products
Science
Learn
Professional
Cellular & Healthy AgingNPN 80146903

NMN 9600 PLUS

NAD+ precursor. Antioxidant support.

NMN 160 mg + trans-resveratrol 80 mg per capsule
60 hard capsules · One capsule daily

Helps in energy metabolism and tissue formation. Provides antioxidants that help protect cells against oxidative damage caused by free radicals.

$39.00 CAD

Adults 18+. Read the label and safety information before use.

01 / Two ingredients

Two ingredients.
Listed clearly.

Understand each ingredient, its amount and the evidence relevant to it.

NMN

160 mg NMN.

Nicotinamide mononucleotide is a precursor involved in NAD+ production. This formula uses synthetic NMN.

TRANS-RESVERATROL

80 mg trans-resveratrol.

The trans form of resveratrol, a polyphenol studied in cellular signalling, metabolism and ageing biology.

02 / Inside the capsule

A closer look.
Two ingredients, individually listed.

Capsule and powder illustration; not a measured release process inside the body.
Formula clarity

160 mg + 80 mg.

NMN — 160 mg per capsule.
trans-Resveratrol — 80 mg per capsule.

Sources in the product licence

NMN: nicotinamide mononucleotide (synthetic).
trans-Resveratrol: resveratrol; Reynoutria japonica root.

Non-medicinal ingredients

Hypromellose, magnesium stearate, microcrystalline cellulose.

03 / Ingredient science

What is NMN?

NMN is a precursor used in the body’s production of NAD+. NAD+ participates in cellular metabolism. This product’s licence identifies NMN as a NAD+ precursor that helps support biological functions involved in maintaining good health.

TRANS-RESVERATROL

Resveratrol.
Read the research in context.

Resveratrol has a long history in ageing research. Early laboratory and mouse findings led to human studies, which have produced mixed metabolic results. These studies do not establish that this formula extends human life.

04 / Follow the evidence

What was studied.
What remains uncertain.

Explore human ingredient studies, laboratory research and a direct NMN–resveratrol animal study. Study doses and formulations differ from this product. These are not clinical trials of this finished formula.

Bai LB et al. · 2022

Improvement of tissue-specific distribution and biotransformation potential of nicotinamide mononucleotide in combination with ginsenosides or resveratrol.

Co-administration changed tissue NAD+ responses compared with NMN alone, including higher measured levels in heart and skeletal muscle.

Okabe K et al. · 2022

Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects.

Blood NAD+ increased with NMN supplementation; the monitored physiological and laboratory assessments did not identify obvious adverse effects over the study period.

Yoshino M et al. · 2021

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

Researchers reported improved skeletal-muscle insulin sensitivity and insulin signalling in this specific study population.

Igarashi M et al. · 2022

Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men.

Blood NAD+ increased. Exploratory walking-speed and left-hand grip findings were nominally significant; body composition did not significantly change.

Mills KF et al. · 2016

Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice.

Long-term administration affected several age-associated metabolic and physiological measures in mice.

Timmers S et al. · 2011

Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

The small crossover study reported changes in selected metabolic and mitochondrial measurements.

Poulsen MM et al. · 2013

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

Resveratrol did not significantly improve the primary insulin-sensitivity outcome or the measured metabolic and inflammatory outcomes.

Howitz KT et al. · 2003

Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.

An early paper reported sirtuin-related activity and longer yeast lifespan under its experimental conditions.

Kaeberlein M et al. · 2005

Substrate-specific activation of sirtuins by resveratrol.

Activation depended on the assay substrate, and the investigators did not detect the claimed yeast lifespan effect in the tested strains.

Baur JA et al. · 2006

Resveratrol improves health and survival of mice on a high-calorie diet.

Resveratrol improved survival and selected physiological measures compared with the high-calorie-diet control group.

Pearson KJ et al. · 2008

Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.

Several age-associated measures improved, but standard-diet mice did not live longer when treatment began in midlife.

05 / Authorized purpose

A defined purpose.
A verifiable licence.

NPN 80146903

Helps in energy metabolism and tissue formation. Provides antioxidants that help protect cells against oxidative damage caused by free radicals.

Illustration of a hand holding a white capsule
Capsule illustration.
06 / Daily use

One capsule.
A daily routine.

1capsule daily
60capsules per pack

Adults 18 years and over: take 1 capsule once daily.

Ask a health care practitioner for use beyond 12 weeks.

Ask a health care practitioner before use if you are pregnant or breastfeeding. Ask a health care practitioner before use if you have diabetes. Ask a health care practitioner before use if you are taking medications or any other health products, as resveratrol may alter their effectiveness.

Ask a health care practitioner for use beyond 12 weeks.

07 / Formula transparency

Know both
ingredients.

Both medicinal ingredients are listed with their own amount per capsule.

NMN160 mg
TRANS-RESVERATROL80 mg

Medicinal ingredients · per capsule

Non-medicinal ingredients

Hypromellose, magnesium stearate, microcrystalline cellulose.

08 / Quality + verification

Different questions.
Different sources.

Examine the product licence, ingredient information and the scope of research separately.

09 / Questions, answered

A little more
understanding.

What are the two main ingredients?

Each capsule contains 160 mg NMN and 80 mg trans-resveratrol.

Has this exact formula been tested in the linked trials?

The selected papers examine individual ingredients or an animal combination. They are not clinical trials of DR.MORGAN NMN 9600 PLUS.

Do the studies prove a longer human lifespan?

No. The selected human trials did not establish lifespan extension. Animal and laboratory findings need to be read in their own context.

How do I take it?

Adults 18 years and over: Take 1 capsule once daily. Ask a health care practitioner for use beyond 12 weeks. Read all warnings before use.

Licensed product information.

Dr. Morgan NMN 9600 Plus · 60 capsules · NPN 80146903

Licence holder: MORGAN NATURAL HEALTH PRODUCTS Inc.

Recommended uses

  • Helps maintain the body's ability to metabolize nutrients.
  • Helps in energy metabolism and tissue formation.
  • NMN is a NAD+ precursor which helps to support biological functions which play a key role in the maintenance of good health.
  • Provides antioxidants that help protect cells against oxidative damage caused by free radicals.

Medicinal ingredients · per capsule

NMN (synthetic) — 160 mg.
trans-Resveratrol — 80 mg.

Dose and caution

Adults 18 years and over: take 1 capsule once daily.

Ask a health care practitioner for use beyond 12 weeks.

Ask a health care practitioner before use if you are pregnant or breastfeeding. Ask a health care practitioner before use if you have diabetes. Ask a health care practitioner before use if you are taking medications or any other health products, as resveratrol may alter their effectiveness.

Read the official licence record ↗

Inside each capsule.

NMN — 160 mg per capsule.
trans-Resveratrol — 80 mg per capsule.

Sources in the product licence

NMN: nicotinamide mononucleotide (synthetic).
trans-Resveratrol: resveratrol; Reynoutria japonica root.

Non-medicinal ingredients

Hypromellose, magnesium stearate, microcrystalline cellulose.

Directions and cautions.

Adults 18 years and over: take 1 capsule once daily.

Ask a health care practitioner for use beyond 12 weeks.

Ask a health care practitioner before use if you are pregnant or breastfeeding. Ask a health care practitioner before use if you have diabetes. Ask a health care practitioner before use if you are taking medications or any other health products, as resveratrol may alter their effectiveness.

Ask a health care practitioner for use beyond 12 weeks.

Batch documentation.

A batch report identifies a particular sample and the tests performed. It is separate from evidence of clinical efficacy.

Contact DR.MORGAN with the lot number on your bottle to ask about available batch documentation.

Explore nmn research.

Read the selected studies with their tested dose, population and limitations.

Open the evidence library ↗

Explore resveratrol research.

Read the selected studies with their tested dose, population and limitations.

Open the evidence library ↗

Bai LB et al. · 2022

Study type

Animal combination study

Participants / model

Male C57/BL6 mice aged 6–8 weeks; 3 animals per group per sampling time

Dose

NMN 500 mg/kg plus resveratrol 50 mg/kg, administered sequentially by mouth

Duration

Acute sampling at 1, 2, 4 and 6 hours

Findings

Co-administration changed tissue NAD+ responses compared with NMN alone, including higher measured levels in heart and skeletal muscle.

Limitations

Small animal experiment, not a human trial or longevity study. No resveratrol-only arm or formal interaction analysis establishing synergy. The study used a 10:1 mass ratio; this product supplies 2:1. These measurements cannot predict tissue changes at this product’s dose.

Product relevance

Direct combination research background; not evidence of clinical synergy for this finished product.

Funding / disclosures

Authors declared no conflicts; funding not fully assessed.

Read the original publication ↗

Okabe K et al. · 2022

Study type

Human randomized trial

Participants / model

30 healthy adults; 15 NMN and 15 placebo

Dose

NMN 250 mg/day

Duration

12 weeks

Findings

Blood NAD+ increased with NMN supplementation; the monitored physiological and laboratory assessments did not identify obvious adverse effects over the study period.

Limitations

Small, short trial of NMN alone at a different dose. A blood biomarker increase does not establish longer life or broad clinical benefit, and short-term tolerability is not a universal safety guarantee.

Product relevance

NAD+ precursor and human biomarker context; not this 160 mg + 80 mg formula.

Funding / disclosures

Funded by Mitsubishi Corporation Life Sciences; several authors were employees and supplied study material. Additional facility support is listed in the paper.

Read the original publication ↗

Yoshino M et al. · 2021

Study type

Human randomized trial

Participants / model

25 postmenopausal women with overweight/obesity and prediabetes

Dose

NMN 250 mg/day

Duration

10 weeks

Findings

Researchers reported improved skeletal-muscle insulin sensitivity and insulin signalling in this specific study population.

Limitations

Small, selected population; NMN alone and a different dose. Not a diabetes-treatment claim, not a longevity endpoint, and not a trial of DR.MORGAN NMN 9600 PLUS.

Product relevance

Human ingredient research, specific to the population and outcomes studied.

Funding / disclosures

NIH/NIA/NIDDK and other grants are indexed in yoshino-core.json; complete conflict disclosure not assessed in the retrieved abstract.

Read the original publication ↗

Igarashi M et al. · 2022

Study type

Human randomized trial

Participants / model

42 older men randomized; 22 participants’ 12-week data excluded after supplement-allocation error

Dose

NMN 250 mg/day

Duration

6 and 12 weeks

Findings

Blood NAD+ increased. Exploratory walking-speed and left-hand grip findings were nominally significant; body composition did not significantly change.

Limitations

A supplier allocation error substantially reduced the 12-week analysis. Exploratory multiple comparisons were not corrected. The mobility findings require confirmation.

Product relevance

Secondary human context; read with the methodological caveat.

Funding / disclosures

Funded by Mitsubishi Corporation Life Sciences, which supplied NMN; three authors were employees.

Read the original publication ↗

Mills KF et al. · 2016

Study type

Animal study

Participants / model

Normally ageing C57BL/6N mice

Dose

NMN 100 or 300 mg/kg/day in drinking water

Duration

12 months

Findings

Long-term administration affected several age-associated metabolic and physiological measures in mice.

Limitations

Animal physiology study with doses unlike this product. The reported findings do not demonstrate human lifespan extension or this finished product’s effects.

Product relevance

Background on why NAD+ precursors are investigated in ageing biology.

Funding / disclosures

Not fully assessed; independence cannot be assessed from the available disclosure.

Read the original publication ↗

Timmers S et al. · 2011

Study type

Human randomized crossover trial

Participants / model

11 men with obesity

Dose

Resveratrol 150 mg/day

Duration

30 days per intervention

Findings

The small crossover study reported changes in selected metabolic and mitochondrial measurements.

Limitations

Short trial, small selected population and a different dose. Other human trials have not reproduced all metabolic benefits; not a human longevity result.

Product relevance

Ingredient research context; read alongside Poulsen 2013.

Funding / disclosures

Not fully assessed; independence cannot be assessed from the available disclosure.

Read the original publication ↗

Poulsen MM et al. · 2013

Study type

Human randomized trial

Participants / model

24 otherwise healthy men with obesity

Dose

trans-Resveratrol 500 mg three times daily (1,500 mg/day)

Duration

4 weeks

Findings

Resveratrol did not significantly improve the primary insulin-sensitivity outcome or the measured metabolic and inflammatory outcomes.

Limitations

Different dose, design and endpoints from the small positive crossover trial. A high-dose null result does not prove this lower-dose formula ineffective; it does limit blanket metabolic-benefit claims.

Product relevance

Necessary context for mixed human findings.

Funding / disclosures

Investigator-initiated; Danish public and foundation funding listed. Authors reported no other relevant conflicts.

Read the original publication ↗

Howitz KT et al. · 2003

Study type

Laboratory and yeast study

Participants / model

Enzyme assays and Saccharomyces cerevisiae

Dose

Laboratory exposures; no human oral dose

Duration

Laboratory and yeast lifespan experiments

Findings

An early paper reported sirtuin-related activity and longer yeast lifespan under its experimental conditions.

Limitations

Historical laboratory finding, not human longevity evidence. Later work questioned assay and substrate dependence; the Kaeberlein study provides additional context.

Product relevance

Explains resveratrol’s early place in ageing research, not evidence for a human longevity regimen.

Funding / disclosures

Not fully assessed; independence cannot be assessed from the available disclosure.

Read the original publication ↗

Kaeberlein M et al. · 2005

Study type

Laboratory and yeast study

Participants / model

Enzyme assays and three yeast strain backgrounds

Dose

Laboratory exposures; no human oral dose

Duration

Laboratory and yeast experiments

Findings

Activation depended on the assay substrate, and the investigators did not detect the claimed yeast lifespan effect in the tested strains.

Limitations

Does not settle every mechanism in later studies. It prevents a simplified claim that resveratrol universally switches on a longevity pathway.

Product relevance

Methodological context paired with the 2003 paper.

Funding / disclosures

Not fully assessed; independence cannot be assessed from the available disclosure.

Read the original publication ↗

Baur JA et al. · 2006

Study type

Animal study

Participants / model

Middle-aged mice receiving a high-calorie diet

Dose

Dietary resveratrol; detailed dose not reproduced on the public card

Duration

Long-term survival follow-up

Findings

Resveratrol improved survival and selected physiological measures compared with the high-calorie-diet control group.

Limitations

Specific mouse diet model; not proof of longer life in healthy people. Subsequent standard-diet findings provide additional context.

Product relevance

Historical ageing-research context.

Funding / disclosures

Competing financial interests declared; details require the journal disclosure.

Read the original publication ↗

Pearson KJ et al. · 2008

Study type

Animal study

Participants / model

Mice under different feeding conditions; standard-diet treatment begun at 12 months

Dose

Dietary resveratrol across experimental regimens

Duration

Long-term physiological and survival follow-up

Findings

Several age-associated measures improved, but standard-diet mice did not live longer when treatment began in midlife.

Limitations

Physiological changes and lifespan are distinct endpoints. Animal results cannot establish human anti-ageing benefits.

Product relevance

Completes the historical story and prevents a selective lifespan claim.

Funding / disclosures

Not fully assessed; independence cannot be assessed from the available disclosure.

Read the original publication ↗

Product image.

Your cart.

Your cart is empty.

Explore products

View full cart →